Pharmaceutical giant Pfizer has agreed to pay $35 million to settle allegations that it unlawfully hindered the sale of Lipitor, a drug prescribed to lower cholesterol, resulting in buyers paying ...

When a novel coronavirus struck in early 2020, Pfizer’sPFE-0.74%decrease; red down pointing triangle chief executive, Dr. Albert Bourla, saw an opportunity to help save the world. He pushed the ...

For Pfizer PFE-0.74%decrease; red down pointing triangle Chief Executive Officer Albert Bourla, the activist campaign launched by Starboard Value marks a pivotal moment in his career. For ...

Pfizer's COVID-19 products continue to generate significant cash flow that helps bolster the company's dividend. The big drugmaker has opportunities to monetize assets to raise additional cash ...

Pfizer offers a generous 5.73% dividend yield. The stock is trading at an attractive forward P/E of 9.5x 2026 earnings. The company has multiple potential growth drivers in its pipeline. Pfizer's ...

NEW YORK, Oct 15 (Reuters) - Pfizer appointed a former chief executive officer at Vanguard, the drug giant's biggest investor, to its board on Tuesday as it faces pressure from activist hedge fund ...

Albert Bourla, who four years ago led Pfizer through its scientific and financial triumph during the covid-19 pandemic, is suddenly facing a new challenge from a large shareholder frustrated over ...

Are you a print subscriber? Activate your account. By Tim Nudd - 1 hour 14 min ago By Adrianne Pasquarelli - 5 hours 42 min ago By Erika Wheless - 5 hours 42 min ago By Brian Bonilla - 5 hours 42 ...

Pfizer placed a $6.7 billion bet on the outcome of two phase 3 trials of Arena Pharmaceuticals' etrasimod in ulcerative colitis (UC) when it acquired the company earlier this year, and the gamble ...

A boost from COVID-19 treatment sales helped bush Pfizer to a better-than-expected third quarter and higher forecast for the year. Demand for the drugmaker’s Paxlovid treatment spurred by the ...

(Reuters) -Pfizer CEO Albert Bourla, under pressure from activist hedge fund Starboard Value, made his case to Wall Street on Tuesday that the drugmaker's turnaround is succeeding after it ...